0.99
-1.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Vaccinex
From its filings with the US Securities and Exchange Commission
Vaccinex is based in Rochester, New York and is incorporated in Delaware. Its shares trade on OTC under the ticker VCNX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2024, it reported revenue of $601,000 and a net loss of $18.6m. At that date it held total assets of $2.6m and shareholders' equity of −$2.5m.
We are a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. We believe we are the leader in the field of semaphorin 4D, or SEMA4D, biology and that we are the only company targeting SEMA4D as a potential treatment for neurodegenerative diseases, cancer, and autoimmune disorders. SEMA4D is an extracellular signaling molecule that regulates the activity of immune and inflammatory cells at sites of injury, cancer, or infection. We have used our SEMA4D antibody platform and our extensive knowledge of SEMA4D biology to develop our lead product candidate, pepinemab, an antibody that we believe utilizes novel mechanisms of action. We are focused on developing pepinemab for the treatment of Alzheimer’s disease, or AD and as our resources allow, also developing pepinemab for head and neck cancer, and pancreatic cancer. Additionally, third party investigators have studied pepinemab in clinical trials in breast cancer, as well as in “window of opportunity” studies in other indications, including melanoma. We have developed multiple proprietary platform technologies and product candidates to address serious diseases or conditions that have a substantial impact on day-to-day functioning and for which treatment is not addressed adequately by available therapies.
Quoted from its 10-K, filed 15 Apr 2025. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 9 Aug 2018
- Employees
- 23
- Website
- vaccinex.com ↗
- Head office
- 1895 MOUNT HOPE AVE, ROCHESTER, NY, 14620
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Albert FriedbergChairman of the Board, since 2001
- Dr. Maurice ZaudererPresident, Chief Executive Officer, Director, since 2001$447,988
- Ms. Jill SanchezChief Financial Officer
- Dr. Elizabeth EvansChief Operating Officer, Senior Vice President - Translational Medicine and Discovery$317,050
- Dr. Ernest SmithSenior Vice President - Research, Chief Scientific Officer$347,523
- Mr. Jacob FriebergIndependent Director$75,000
- Mr. Michael RiceFounding Partner, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Vaccinex Inc focuses on clinical-stage biotechnology with a strong emphasis on cancer and neurodegenerative diseases.
- The company's SEMA4D antibody platform targets multiple serious conditions including NSCLC and Huntington's disease.
- Vaccinex employs 23 full-time employees with a focus on developing innovative biotherapeutics for unmet medical needs.
Weaknesses
- Vaccinex has only 23 employees, which may limit its operational capacity and research capabilities.
- The company's IPO in 2018 has not yet led to significant revenue generation or market expansion.
- Vaccinex's product candidates are still in clinical or preclinical stages, delaying potential market entry.
Opportunities
- Vaccinex can leverage its SEMA4D platform to expand into new therapeutic areas like multiple sclerosis and autoimmune disorders.
- The growing biotechnology sector in the US offers opportunities for partnerships and funding.
- Vaccinex's focus on unmet medical needs aligns with increasing global healthcare demands for innovative treatments.
Threats
- Vaccinex faces competition from established biotechnology firms in the US market.
- The high costs of clinical trials and regulatory approvals pose significant financial risks.
- Vaccinex's reliance on a single platform, SEMA4D, increases vulnerability to market shifts.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.